Ru-Based Photocaged Kinase Inhibitors Operative under Deep-Red Light Irradiation

Area of Science:

• Photochemistry
• Materials Science
• Oncology

Background:

• Photoresponsive drug delivery systems often use limited-penetration light.
• Targeted cancer therapy requires precise control over drug activation.
• Ruthenium(II) complexes offer versatile platforms for photopharmacology.

Purpose of the Study:

• To design ruthenium(II) polypyridyl complexes for deep-red light-activated drug release.
• To enable spatiotemporal control over imatinib kinase inhibitor activity.
• To investigate the therapeutic potential in leukemia models.

Main Methods:

• Synthesis of ruthenium(II) complexes with extended donor-π-acceptor ligands.
• Photophysical and photochemical characterization of the complexes.
• In vitro studies using BCR-ABL-positive leukemia cells and 3D tumor spheroids.

Main Results:

• Developed Ru(II) complexes absorbing at deep-red light (660 nm).
• Demonstrated efficient and clean photoinduced release of imatinib.
• Exhibited light-dependent cytotoxicity, apoptosis induction, and BCR-ABL inhibition in leukemia cells.
• Confirmed efficacy in 3D tumor spheroids, indicating good penetration and photoactivation.

Conclusions:

• Established a molecular design for deep-red light-activated Ru(II) photocages.
• Highlighted the potential for spatiotemporally controlled kinase inhibition in cancer therapy.
• Showcased a promising strategy for targeted photodynamic cancer treatment.